The move towards medicine customised for individual patients holds promise in the development of safer and more effective drugs, but there remain various challenges before this potential is realised fully. In the white paper ‘Management and Analysis of Biomarker Data’, analysis company Exploristics outlines solutions to the management, storage, integration, and analysis of large volumes of biomarker data, provided through a partnership with OmicSoft: Array Studio and Array Server.
Scientists at Beiersdorf AG have once again made an important contribution to our understanding of skin: together with researchers of Charité University Medicine Berlin they were able to demonstrate the existence of an inner clock in human skin cells, which controls skin regeneration among other things. Hamburg researchers from the team of Dr. Jörn Hendrik Reuter, Head of the General Skin Care Laboratory at Beiersdorf and Professor Achim Kramer from the Chronobiology Department of Charité Berlin participated in the collaborative research project. ‘The findings from our collaborative research could have a large influence on the skincare of the future,’ Reuter said.
Expanding middle class and increased disposable income will make healthcare more affordable
The growing middle class, increasing incidence of non-communicable diseases (NCDs) and the continued burden of infectious diseases will result in double digit growth in the East and West African pharmaceuticals markets. Pharmaceuticals alleviating chronic conditions, such as hypertension and diabetes, represent lucrative growth opportunities according to growth partnership company, Frost&Sullivan.
Researchers from South Africa’s Council for Scientific and Industrial Research (CSIR) have developed the world’s first injectable medicine from a tobacco plant – an antidote for rabies which could change the way the deadly viral disease is treated worldwide.
Roche has announced results from two studies which showed that a fixed dose of MabThera (rituximab) can be administered subcutaneously (SC), potentially allowing patients to spend less time in infusion centres receiving their MabThera treatment. Specifically, the studies showed that SC injection resulted in non-inferior MabThera concentrations in the blood (pharmacokinetics; PK) compared with standard intravenous (IV) infusion. Overall, SC and IV adverse event (AE) profiles were similar and administration related reactions (ARR) were mostly of mild to moderate intensity. The results were presented at the 54th annual meeting of the American Society of Hematology (ASH) and formed the basis of the line-extension marketing application which was submitted to the European Medicines Agency (EMA) on 4 December 2012.